{"name":"Jun-Won Chung","slug":"jun-won-chung","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"sequential versus triple","genericName":"sequential versus triple","slug":"sequential-versus-triple","indication":"Treatment of Helicobacter pylori infections","status":"marketed"}]}],"pipeline":[{"name":"sequential versus triple","genericName":"sequential versus triple","slug":"sequential-versus-triple","phase":"marketed","mechanism":"Sequential versus triple therapy is used to treat Helicobacter pylori infections by combining antibiotics to eradicate the bacteria.","indications":["Treatment of Helicobacter pylori infections","Eradication of H. pylori in patients with peptic ulcer disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOSXR6Sl9GQU9zaWo1UW1mS0xlSmU5ZkJJZnVKbWoxcGdpb2Nsd1RSUkxELUpyR1haY3ZVUmhGOURjTzdvc0FlQzJOeGVlTFRBWUpDMlowZE1HLWk2UWRnSE1YME9rcUNVX3B4SEpSdXVHQ0lTQnBLVUs1cWxrMGx3RmlHQWdRUzJu?oc=5","date":"2025-12-10","type":"pipeline","source":"조선일보","summary":"Young Executives Signal New Era as Korean Business Leadership Ages Down - 조선일보","headline":"Young Executives Signal New Era as Korean Business Leadership Ages Down - 조선일보","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPWmJnRUJIUy10Z2ExaXdVMm9SWU4yVEhfMnhWREFZcU04ZWZXRVE1Rmo1SVFWSWNjclRpQlhLNzdmbEpqM3haa3BEdHBOaktVbzBNNVc5RWVSS3BGQ3V3QUhfOEdnNkxXWkR4Rmpmbkhoa2FOYUlJQnpuOTVSMDB2ZtIBlAFBVV95cUxQTkRXaFB4TFdVdlFiNnBJQ2dfRmRVQWJVMGtXNUdnaVQwZE92enZQZHlpaDFVVHZFM2RxM1ZLbmJjd2U3SHo5UHpDRkxvLXFQTDBZT0h0bWxQM0RiWFpNdFUwRmxQLXBVN1RpWFNvVks1cmVxYWJibG0tU3d1M29TRmNMSkZ1SC1IbnhXTWYtaVdVSG1I?oc=5","date":"2025-11-16","type":"pipeline","source":"Chosunbiz","summary":"Celltrion chairman Seo Jung-Jin pledges 4 trillion won Korea investment and boosts R&D to 1 trillion won by 2027 - CHOSUNBIZ - Chosunbiz","headline":"Celltrion chairman Seo Jung-Jin pledges 4 trillion won Korea investment and boosts R&D to 1 trillion won by 2027 - CHOSU","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQX1JlY0d1V2s0by1ZNW9IeWVUaUp5QTl4UUVqUWx3MEx2VExKNUYtbVhGT2RpMHdnbkZNNTlfMUVPWDFCaXZvbDBSZC1VcEU3M1czc0JWMTFGMVhrVlVYb1E1ODlCcDJJSmUxaHFaVldsNERaVjdCemM4Wk1sblhoY9IBlAFBVV95cUxQdkdPTU9rY0FJbDhSY085c2RucEllaTJOQWFHczliS1RJVEVQTkU0Y0h4bUpCX3JRWkJHVk1jYXBfSGFqTTNFd1hCdm8wMXBrb3NidnY5Q0tWX2hlOF8tNUNfSm1zUlZ3bVI3Qko2T1BwSUVpbHJJQXdxMWxtNmJrbW9BMFZWMm1NMEhHMUI2dG4xQllW?oc=5","date":"2025-11-13","type":"pipeline","source":"Chosunbiz","summary":"Korean pharma groups accelerate generational shift as family heirs assume CEO roles - CHOSUNBIZ - Chosunbiz","headline":"Korean pharma groups accelerate generational shift as family heirs assume CEO roles - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBEcUVkTkRtU2VkVEp1cWtmNE1FRDBTdVpBcE5ta0RoZ01mVTNCeDlDZUg2eEx4RndPbU1XWUFFLVNwVS1IZWFKR3laVl92MmFxQ1NVUXI5ZEkweGl6QTRpaDlNLV9DVkUza0Rndk9R0gFyQVVfeXFMUExkblY1Q2gtWEVYM2hJSDhTWjRWMDFGQ1N4cy1fak5UZG02algwdDZsQlNiMS1nMDl0azhoT0lNRmdzVURtWnhMMDZBeG13bzg4amdvRldTbl9sdEk0YWZ6WU9QT0F2RFdra040SENtZlBR?oc=5","date":"2024-09-06","type":"pipeline","source":"koreabiomed.com","summary":"'AML treatment advances hindered by limited reimbursement, government delays' - koreabiomed.com","headline":"'AML treatment advances hindered by limited reimbursement, government delays'","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE40UXlJekdkQXRqWFRRWTJsZ256czQ3dEtPVkFRbC1jZlkzcTFGMTBPRGZDOWRtWW9iWVVvZ2NacDc3b0JPeHhjb1c0S05HSl9hODVkNkxsMklzQktQYzE5WjZIS01hZlZoODZVdG5n?oc=5","date":"2024-08-30","type":"pipeline","source":"KED Global","summary":"SK Group’s 3rd-generation daughter comes to the fore - KED Global","headline":"SK Group’s 3rd-generation daughter comes to the fore","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1ZRkRHS2RKamJTamlITG9nLXZhWS1GeHRySFh5RWVwRkh2YWVwakIzZnJEOWNwbHp1SDd6MWpFZ09MaG5DWm1hazBwOW1zb3dnRkdSelNDeXFaM0VDcGNxeW9jZGpYYlVXcU1VbGtn?oc=5","date":"2023-04-04","type":"pipeline","source":"KED Global","summary":"Management dispute over S.Korea’s CTC Bio heats up - KED Global","headline":"Management dispute over S.Korea’s CTC Bio heats up","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}